Asthma

Gossamer Bio Adds $276M in Second Biotech “Unicorn” IPO of 2019

Gossamer Bio, the San Diego-based biotech founded by former Receptos executives, has raised $276 million in its initial public offering, a total that puts it in a rare class among biotechs that have gone public in recent years.

The amount raised surpassed expectations. During the partial federal government shutdown in January, Gossamer announced it would pursue a little-used path to the public markets that required it to fix a share price, which was locked in for 20 days. But shortly thereafter the government reopened, and Gossamer announced it would reroute to the traditional path to the public markets on the terms… Read more »

UNDERWRITERS AND PARTNERS

          

          

            
https://xconomy.com/san-diego/2019/02/07/gossamer-bio-adds-276m-in-second-biotech-unicorn-ipo-of-2019/

Advertisements
READ  Innovate Bioharma CEO Prior Resigns, Chairman Laumas Steps In

Leave a Reply